• Five oral and poster presentations highlight utility of OncoDNA’s comprehensive testing of cancer biomarkers and cancer treatment database

• New OncoDEEP product able to sequence four times as many genes

OncoDNA (“OncoDNA or “the Company”), the healthcare technology company making precision medicine a reality, notes the presentation of the following data by its partners at the European Society for Medical Oncology (ESMO) 2018 Congress, taking place on October 19-23, 2018 in Munich, Germany, highlighting the value of OncoDNA’s proprietary diagnostics services and AI-driven cancer knowledge database.

Jean-Pol Detiffe, Chief Executive Officer of OncoDNA, said:

“The presentations by our partners at this prestigious conference demonstrate the power of OncoDNA’s database and our holistic approach to genomic and molecular profiling. As new drugs and approaches to cancer care continue to rapidly develop, studies like these play a key role in validating OncoDNA’s products and bringing them to the attention of oncologists, hospitals, payors and patients.”

Separately, the Company also announces the launch of a new version of its solid tumor analysis product, OncoDEEP. The new OncoDEEP profiles solid tumor samples by sequencing a total of 313 genes, compared to 75 for the original product. The genes are assessed for links to approved targeted therapies, combined with IHC tests to detect important proteins and with other tests, such as MSI, gene fusion or promoter methylation. This new version of OncoDEEP delivers one of the best sets of data for immunotherapy selection on the market.

The following results will be presented during the ESMO conference:

1. Title: Primary results of the first nationwide molecular screening program in Spain for patients with advanced breast cancer (AGATA SOLTI-1301 study)

   Oral Presentation Number: 284O

   Speaker: Dr. Eva Ciruelos

   Date & Time: Saturday, October 20, 2018; 12.00 - 13.00 CET

   Location: ICM - Room 14b

    

   Using OncoDNA’s tumor analysis and screening services, this study determined that nationwide molecular screening in Spain is feasible. Nearly half of patients had tumors with mutation(s), mostly in PIK3CA, that could potentially be matched to a drug or drug class that could work for the patient

2. Title: Clinical utility of complex multi-platform profiling in metastatic cancer patients

   Poster Presentation Number: 1340P

   Presenter:Prof. Jesus García Foncillas

   Date & Time: Saturday, October 20, 2018; 12.30 - 13.30 CET

   Location: Hall 3 Poster Area

    

   This study found that OncoDNA’s comprehensive molecular profiling technology, which combines immunohistochemistry, next generation sequencing (NGS), and other tests including, DNA methylation, and microsatellite instability (MSI) testing, helped physicians make more informed treatment decisions. Notably, 93% of treatment decisions were made based on OncoDNA’s holistic analysis using its comprehensive molecular profiling, compared with only 27% using NGS data only. Moreover 27% of late-stage patients treated with OncoDNA-recommended therapies had an overall survival of over twelve months, compared to the typical average of no more than six months.

3. Title: Carcinoma of Unknown origin: Deep Genomic profile helps to achieve an accurate diagnosis

   Poster Presentation Number: 1860P

   Presenter:Dr. A. B. Fernandez Díaz

   Date & Time: Saturday, October 20, 2018; 12.30 - 13.30 CET

   Location: Hall 3 Poster Area

    

   In this study, OncoDNA’s OncoDEEP CUP platform for tissue assessment and genotyping was shown to provide an opportunity for CUP patients to benefit from site-specific treatments and personalised therapies. Based on this study, OncoDNA’s solutions are now included in the Spanish SEAP-SEOM consensus statement for cancers of unknown primary origin.

    

4. Title:  The combination of gene and protein expression reflected the efficacy of the targeted therapy in breast cancer

   Poster Presentation Number: 1913P

   Presenter:Dr. E. Seront

   Date & Time: Sunday, October 21, 2018; 13.05 CET

   Location: Hall 3 Poster Area

    

   OncoDNA’s OncoSTRAT&GO, which combines sequencing of oncogenic genes panel and expression analysis of proteins that could be targeted by current antitumoral agents, was show in this study to help identify resistance mechanisms occurring during specific treatments and helped determine potential alternative treatments.

    

5. Title: Preliminary results from a phase 2 trial of tipifarnib in Squamous Cell Carcinomas (SCCs) with HRAS mutations

   Oral Presentation Number: 1046O

   Speaker: Dr Alan L. Ho

   Date & Time: Monday, October 22, 2018; 15.50 CET

   Location: ICM - Room 14b

    

   OncoDNA supported patient enrolment for Kura Oncology’s ongoing HRAS tipifarnib trial in patients with HRAS mutant head and neck squamous cell carcinomas (HNSCC). Tipifarnib is an inhibitor of farnesylation, a key cell signalling process implicated in cancer initiation and resistance to standard therapies.

Contact :